SCHEMBL21724167

SCHEMBL21724167

CCN(CC)Cc1c[nH]c2ccc(Cl)cc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPO P05164 3/20 0.68
GPR84 Q9NQS5 1/20 0.63
HSD17B10 Q99714 2/20 0.62
KDM4E B2RXH2 1/20 0.62
MEN1 O00255 1/20 0.62
ALDH1A1 P00352 1/20 0.62
MAPT P10636 1/20 0.62
HPGD P15428 1/20 0.62
KMT2A Q03164 1/20 0.62
HTR2A P28223 4/20 0.57
SLC6A4 P31645 3/20 0.57
HTR1D P28221 2/20 0.57
HTR1A P08908 2/20 0.57
ADRA2A P08913 1/20 0.57
DRD2 P14416 1/20 0.57
ADRA2B P18089 1/20 0.57
ADRA2C P18825 1/20 0.57
SLC6A2 P23975 1/20 0.57
ADRA1D P25100 1/20 0.57
HTR1B P28222 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL443368 0.84 SLC6A4 (0.68) MPOGPR84HSD17B10KDM4EMEN1
SCHEMBL10119751 0.82 GPR84 (0.73) GPR84HSD17B10MEN1MAPTKMT2A
SCHEMBL24243766 0.81 HTR2A (0.72) MPOGPR84HSD17B10HTR2ASLC6A4
SCHEMBL12464834 0.79 HTR2A (0.71) MPOGPR84HSD17B10MEN1MAPT
SCHEMBL26498347 0.78 GPR84 (0.73) GPR84HSD17B10MEN1MAPTKMT2A
SCHEMBL18383117 0.78 GPR84 (1.00) GPR84HTR2ASLC6A4HTR1DHTR1A
SCHEMBL24243690 0.78 HTR2A (0.71) MPOGPR84HSD17B10HTR2ASLC6A4
SCHEMBL11431998 0.78 GPR84 (0.67) GPR84HSD17B10HTR2ASLC6A4HTR1D
SCHEMBL1027348 0.77 ALDH1A1 (1.00) MPOGPR84HSD17B10KDM4EMEN1
SCHEMBL27396037 0.77 MPO (0.62) MPOGPR84HSD17B10KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371429-B2 Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof RECREO PHARMACEUTICALS LLC (US) 2025-07-29 US disclosed
EP-3836919-A1 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF Recreo Pharmaceuticals Inc. (US) 2021-06-23 EP disclosed
US-20210163479-A1 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF RECREO PHARMACEUTICALS LLC (US) 2021-06-03 US disclosed
CN-112654354-A 1,3,4, 9-tetrahydro-2H-pyrido [3,4-b ] indole derivative compound and application thereof 菲尼克思药业股份有限公司 2021-04-13 CN disclosed
WO-2020037155-A1 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF RECREO PHARMACEUTICALS LLC (US) 2020-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371429-B2 Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof CBR3, CBR1, CYP2B6 MPO 2243/4885GPR84 1958/4885HSD17B10 928/4885
US-20210163479-A1 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNA1, FOXM1 MPO 2918/4885GPR84 1785/4885HSD17B10 2407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.